Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

first 48 weeks of treatment. For example, in CAPACITY 2 and CAPACITY 1 the Week 48 rank ANCOVA p values were 0.001 and 0.005; the relative reductions in LS means from the repeated measures analysis were 46% and 29%, respectively. The difference between the CAPACITY 2 and CAPACITY 1 primary endpoint results at Week 72 may have been due to a modest attenuation in the rate of FVC decline in the placebo group subsequent to Week 48 in CAPACITY 1.

Secondary Endpoint Results

In CAPACITY 2, pirfenidone treatment was associated with a statistically significant effect on the pre-specified secondary endpoints of PFS (p = 0.023) and Categorical Change in FVC (p = 0.001) when compared to placebo. A PFS event was defined in the study protocol as the time to death, a 10% decrease in FVC or a 15% decrease in DL(CO). In CAPACITY 1, pirfenidone treatment was associated with a statistically significant effect in the pre-specified secondary endpoint of Six-Minute Walk Test distance (p = 0.001) when compared to placebo. There were no other statistically significant findings on any of the other pre-specified secondary endpoints in either study and pirfenidone treatment was not associated with a worse outcome on any endpoints.

Although pooled analyses of secondary endpoints were pre-specified in the study protocol, these analyses are nonetheless considered exploratory because the primary endpoint of both studies was not met. Analyses of pooled data for the pre-specified secondary endpoints of both CAPACITY studies showed a treatment effect favoring pirfenidone on three: PFS (p = 0.029); Categorical FVC Change (p = 0.003) and Six-Minute Walk Test distance (p = 0.004). While the studies were not powered to demonstrate an effect on overall survival, the pooled hazard ratio (pirfenidone: placebo) was 0.78 (p= 0.326).

Safety and Tolerability Results

Safety data from both studies show that pirfenidone wa
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Savoury Systems International (SSI), ... Dale Braddy to Southeastern USA Sales Broker. Braddy’s new ... muscle in the Southeast. , In 2004 ... and supplier to food processors and industrial manufacturers. ... the food industry and has over 25 years of ...
(Date:5/21/2013)... May 21, 2013 Smarter Security, Inc., ... solutions, today announced that Genzyme, a Sanofi company and ... Door Detective® CL for a multi-use facility in the ... four other Genzyme buildings, this latest order underscores the ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
... , MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - YM BioSciences ... life sciences product development company that identifies and advances ... stages of development, today reported additional results from a ... diffuse intrinsic pontine glioma (DIPG). The updates to the ...
... , - Influenza: 50/50 joint venture agreement signed ... and pandemic flu, manufacturing facility, ... - Thrombolytic: Nears licensing and sales of KINLYTIC(TM) thrombolytic, ... 25% of the dairy semen collection centres now under, ...
... Reportlinker.com announces that a new ... its catalogue. , Worldwide ... Electron Microscope Market Shares, Strategies, and ... , http://www.reportlinker.com/p0153912/Worldwide-Optical-Transmission-TEM-and-Scanning-SEM-Electron-Microscope-Market-Shares-Strategies-and-Forecasts-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ...
Cached Biology Technology:YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 4Microbix Biosystems Provides a Corporate Update 2Microbix Biosystems Provides a Corporate Update 3Microbix Biosystems Provides a Corporate Update 4Microbix Biosystems Provides a Corporate Update 5Microbix Biosystems Provides a Corporate Update 6Microbix Biosystems Provides a Corporate Update 7Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 2Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 3Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 4Reportlinker Adds Worldwide Optical, Transmission TEM, and Scanning SEM Electron Microscope Market Shares, Strategies, and Forecasts, 2009 to 2015 5
(Date:5/22/2013)... pneumophila bacteria is responsible for legionellosis, an infectious ... infect us, this pathogen has developed a complex method ... our cells, thus avoiding these acting against the infectious ... centre, CIC bioGUNE, in which teams from the National ... National Supercomputation Centre in Barcelona (BSC) have also participated, ...
(Date:5/22/2013)... screening for prostate cancer could become as easy for ... to UC Irvine research published today in the ... more than a decade of work, UC Irvine chemists ... markers for prostate cancer in urine, meaning that the ... and at dramatically lower cost. The same technology could ...
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2
... Information System will provide valuable information for assessing environmental ... Environmental Health Sciences (NIEHS), one of the National Institutes ... up-to-date data to public health and safety workers on ... well as demographic information for local populations. ...
... million from the Grand Challenges in Global health initiative ... to humans to aid in testing the safety and ... & Melinda Gates Foundation, the Yale project will be ... Chair of Immunobiology at Yale University School of Medicine, ...
... A new website with a Global Information System will ... Hurricane Katrina. The National Institute of Environmental Health Sciences ... the website to provide the most up-to-date data to ... waters, infrastructure and industry maps, as well as demographic ...
Cached Biology News:FDA approves child-friendly AIDS medicine 2Grand Challenges in Global Health initiative funds Yale project 2NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina 2
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
anti-achaete...
... Oct6 ( Abpromise for all tested applications). ... to KLH derived from within residues 1 - ... acid sequence is proprietary) (Peptide ... Entrez Gene ID: 5453 ...
Biology Products: